Analyst Ratings for Royalty Pharma (RPRX)
RPRX Rating Summary
RPRX Price Target Summary
- Highest: $64.00 (Morgan Stanley)
- Lowest: $50.00 (TD Cowen)
- Average: $56.00
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$56.00 (+5.7%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 79%
Avg. $ Target:
$56.00 (+5.7%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 79%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/30/2026 | UBS » Updated 4/21/2026 |
Ashwani Verma | Upgrade | Buy (Neutral) |
57.00 (51.00) |
40.41 (52.96) |
31.06% | Details |
| 9/30/2025 | Goldman Sachs » Updated 5/7/2026 |
Asad Haider | New Coverage | Buy (N/A) |
59.00 (51.00) |
35.25 (52.96) |
50.24% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
